Troy Farah
- Troy Farah is an independent journalist, documentary filmmaker, podcast producer and he also sometimes takes photographs of bugs and stuff. His reporting on science, drug policy, public health, climate change and bugs and stuff has appeared in VICE, The Guardian, WIRED, Ars Technica, Undark, Discover Magazine and others. He was nominated for an Emmy for his work on the Fusion documentary “Trumpland” (2016) and continues to make documentary films. He lives in California’s High Desert with his wife and two cuddly pitbulls. Troy co-hosts the drug policy and science podcast Narcotica and you can follow him on LinkedIn and Twitter @filth_filler.
Latest Articles
*New Post Categories
Breaking News: Oregon Legalizes Psilocybin Therapy
Under the new policy, licensed facilitators can give psilocybin to adults over 21 in therapeutic contexts.
FEATURES
Scientists are Using AI to Develop New Psychedelic Drugs
Using supercomputers and machine learning, the next generation of psychedelics may look like nothing we've ever seen before.
FEATURES
Meet the Psychedelic Rapper Running for New York City Mayor
The New York rapper and mayor hopeful Paperboy Prince is challenging mainstream politics with a trippy message of love.
FEATURES
MDMA-Assisted Therapy is Less Effective if You Take Antidepressants
A new analysis of four MDMA studies found that a history of taking antidepressants can make the treatment less effective.
FEATURES
Where Will Psychedelics and Other Drugs Be Decriminalized Next?
Drug decriminalization is taking the world by storm—from Vancouver to Vermont, Washington and California, efforts to bring down prohibition are skyrocketing.
FEATURES
What Removing the “Hallucinations” from Psychedelics Means for Psychotherapy
A growing number of companies and researchers are attempting to make psychedelics that don’t cause hallucinations or visions. But will they work as well?
FEATURES
Breaking News: Oregon Legalizes Psilocybin Therapy
Under the new policy, licensed facilitators can give psilocybin to adults over 21 in therapeutic contexts.
FEATURES
Psychedelic Gold Rush? Psilocybin Startup Compass Pathways Goes Public at More than $1B
Here's why Wall Street is starting to see the value in psychedelics.
FEATURES
After Permitting Psilocybin for Terminal Patients, Canada Could Open the Door to Psychedelics
Some Canadians with life-threatening illnesses can now try magic mushrooms to ease their mind. But it could open the door to much more for the Great White North’s psychedelic scene.
Equity + Indigenous Reciprocity
Is it Worth Kidnapping Toads to Extract their Psychedelic Venom—When You Could Make it In a Lab?
The debate over synthetic and toad-derived 5-MeO-DMT.
FEATURES
Redesigning Psychedelic Mushrooms to Never Cause a “Bad Trip”
The key to "good trips only" may lie in aeruginascin, the CBD of psilocybin mushrooms.
FEATURES
Psychedelics on the Stock Exchange?
In the wake of the cannabis green rush, investors are eyeing psychedelics, while Canadian pharma company Mindmed aims to go public this March.
FEATURES
Why You Need to be Careful About the Ketamine Clinic You Choose
Ketamine could pave the way for legal psychedelics—if careless clinics don’t get in the way
FEATURES
This Company is Developing a Drug Based on Ibogaine for the Opioid Crisis
18-MC allegedly puts an end to unhealthy cravings while sparing patients a brutal trip